A pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX) vaccination in patients with INOPERABLE metastatic colorectal cancer.

Trial Profile

A pilot study to assess the effect of regulatory T cell depletion on 5T4-containing MVA (TROVAX) vaccination in patients with INOPERABLE metastatic colorectal cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs MVA 5T4 (Primary) ; Cyclophosphamide
  • Indications Colorectal cancer
  • Focus Pharmacodynamics
  • Acronyms TaCTiCC
  • Most Recent Events

    • 17 Mar 2017 Results have been published in an Oxford BioMedica financial report.
    • 17 Mar 2017 According to an Oxford BioMedica media release, data from the study has been presented in a oster at the American Society of Clinical Oncology and Society for Immunotherapy of Cancer (ASCO-SITC) symposium.
    • 15 Apr 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top